Q-omics provides the consensus-scored PPP6R3 profile across patient tissues and cancer cell-line models. PPP6R3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PPP6R3 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PPP6R3 RNA expression shows 20,974 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where PPP6R3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP6R3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP6R3 survival associations across molecular data types. PPP6R3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP6R3 RNA expression–survival associations across cancer types. High PPP6R3 expression shows unfavorable associations in ACC, UVM, CESC, KICH and PAAD, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PPP6R3 RNA expression.
This table summarizes PPP6R3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PPP6R3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP6R3 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, BRCA and LUSC. The THCA box plot shows higher PPP6R3 RNA expression in normal versus tumor tissue (log2 FC = −0.801, t-test p < 0.001).
This table shows molecular features associated with PPP6R3 in patient tissues and cancer cell lines. In patient samples, PPP6R3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP6R3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
